Even substances we consider vital to life can harbor unexpected roles
En los laboratorios de la Universidad de Würzburg, investigadores alemanes han descubierto que la vitamina B2, un nutriente considerado durante décadas como guardián de la salud celular, también puede convertirse en aliada involuntaria del cáncer. Al activar una proteína llamada FSP1, la riboflavina refuerza el escudo que protege a las células tumorales de la ferroptosis, una forma natural de muerte celular programada. El hallazgo no condena a la vitamina, sino que ilumina una paradoja más profunda: los mismos mecanismos que sostienen la vida pueden, en contextos patológicos, sostener también la enfermedad.
- Una vitamina presente en alimentos cotidianos como la leche y los huevos está siendo explotada por las células cancerosas para escapar de su propia destrucción natural.
- El descubrimiento genera tensión en el campo oncológico, pues obliga a reconsiderar el papel de nutrientes esenciales dentro del microambiente tumoral.
- En experimentos de laboratorio, reducir la disponibilidad de B2 o introducir roseofllavina —un compuesto estructuralmente similar— hizo que las células cancerosas murieran con notable eficacia.
- El equipo de Friedmann Angeli trabaja ahora en inhibidores del metabolismo de la B2 que actúen selectivamente en tumores sin dañar el tejido sano.
- Los ensayos en humanos aún están a años de distancia, pero el proyecto DeciFerr, respaldado con dos millones de euros del Consejo Europeo de Investigación, mantiene el avance en curso.
Un equipo de investigadores alemanes de la Universidad Julius-Maximilians de Würzburg ha publicado en Nature Cell Biology un hallazgo que reencuadra nuestra comprensión de un nutriente familiar: la vitamina B2, o riboflavina, no solo protege las células sanas del daño oxidativo, sino que también puede proteger a las células cancerosas de la ferroptosis, un proceso natural de muerte celular programada.
El mecanismo identificado involucra a la proteína FSP1, que actúa como escudo biológico contra la destrucción celular. La vitamina B2 activa esta proteína, reforzando las defensas de los tumores. Cuando los investigadores, liderados por José Pedro Friedmann Angeli, redujeron la disponibilidad de B2 en modelos de laboratorio, las células cancerosas se volvieron significativamente más vulnerables. La introducción de roseofllavina, un compuesto similar a la B2, produjo la muerte tumoral incluso en concentraciones muy bajas.
La ferroptosis ha ganado protagonismo en la investigación oncológica por una razón particular: a diferencia de otras formas de muerte celular, no desencadena inflamación generalizada, lo que la convierte en un objetivo terapéutico atractivo. Muchos tumores han desarrollado mecanismos para evitarla; este estudio demuestra que la B2 forma parte de ese arsenal defensivo.
El siguiente paso del equipo es desarrollar inhibidores más potentes del metabolismo de la B2 que actúen de forma selectiva en células tumorales, preservando las sanas. Las pruebas preclínicas están en marcha dentro del proyecto DeciFerr, financiado por el Consejo Europeo de Investigación. Los ensayos en humanos aún están lejos, pero el descubrimiento ha cristalizado una verdad incómoda: lo que mantiene vivo al organismo puede, en el contexto equivocado, mantener vivo también al cáncer.
A team of German researchers has uncovered an uncomfortable paradox: a nutrient long celebrated as essential to human health may also be helping cancer cells survive. The discovery, made at Julius-Maximilians-Universität Würzburg and published in Nature Cell Biology, reveals that vitamin B2—also known as riboflavina—plays a role in protecting tumors from a natural form of cellular death called ferroptosis. The finding does not suggest that the vitamin itself is harmful. Rather, it exposes a mechanism by which cancer cells exploit one of the body's most fundamental nutrients to shield themselves from destruction.
For decades, vitamins have been understood primarily through the lens of deficiency and disease prevention. We take them to stay healthy, to maintain energy, to protect our tissues. Vitamin B2 is no exception. It participates in cellular energy production and guards against oxidative damage. It appears in everyday foods—milk, eggs, meat, leafy greens. But researchers led by José Pedro Friedmann Angeli observed something unexpected: the very protective capacity that makes B2 essential to human life can be weaponized by malignant cells. When the team reduced the availability of this vitamin in laboratory models, cancer cells became dramatically more vulnerable to ferroptosis. The inverse was also true. When they introduced roseoflavin, a naturally occurring compound structurally similar to B2, tumor cells died even at very low concentrations.
The mechanism at work involves a protein called FSP1, which reinforces cellular defenses against unwanted destruction. Vitamin B2 acts as an activator of this protein, essentially strengthening a biological shield around cancer cells. Through cell culture experiments and genetic editing, Friedmann Angeli's team demonstrated that interfering with this metabolic pathway is technically feasible. The implications are significant: if researchers can develop inhibitors that block B2 metabolism specifically in tumor cells, they may be able to strip away one of cancer's survival strategies.
Ferroptosis itself has become a focal point of cancer research in recent years, though its importance extends far beyond oncology. Unlike other forms of programmed cell death, ferroptosis is triggered by iron-related oxidative damage and occurs without triggering the widespread inflammation that can harm surrounding tissue. This makes it an attractive target for therapy. Many cancer cells have evolved sophisticated mechanisms to avoid ferroptosis altogether. The new research shows that vitamin B2 is part of that defensive arsenal. But ferroptosis also appears to play roles in neurodegenerative diseases and in damage from organ transplants or ischemia-reperfusion injuries. Understanding how to manipulate this process could open doors across multiple medical fields.
The work is part of a larger initiative called DeciFerr, funded by the European Research Council with approximately two million euros. The project is specifically designed to study the mechanisms regulating ferroptosis in cancer. Friedmann Angeli's team is now focused on developing more potent inhibitors—drugs that could block B2 metabolism in tumor cells while leaving healthy cells unaffected. The next phase involves testing these compounds in preclinical models to determine whether they can genuinely increase tumor sensitivity to cell death. Human trials remain years away, and significant hurdles remain before any of this reaches patients. Yet the discovery has crystallized an important insight within the scientific community: even substances we consider vital to life can harbor unexpected roles when they encounter complex diseases. The vitamin that keeps us healthy may, in the wrong cellular context, be keeping cancer alive.
Notable Quotes
Intervening on this metabolic pathway is technically possible and could become a promising tool in oncology— José Pedro Friedmann Angeli, lead researcher
The Hearth Conversation Another angle on the story
Why does it matter that B2 specifically activates this FSP1 protein? Couldn't cancer cells just find another way to protect themselves?
They probably could, eventually. But right now, FSP1 is one of the main mechanisms tumors use to resist ferroptosis. If you can block that pathway, you're not just slowing cancer down—you're removing one of its escape routes. It's about exploiting a specific vulnerability.
So you're saying this isn't a cure. It's a tool to make existing treatments work better?
Exactly. The real power is in combination. If you can make a tumor vulnerable to ferroptosis through B2 inhibition, then other therapies—chemotherapy, immunotherapy—might work more effectively. You're removing the shield.
The vitamin is found in normal food. Won't blocking it harm healthy cells too?
That's the central challenge. The goal is to develop inhibitors that target B2 metabolism specifically in cancer cells, not throughout the body. It's technically possible but requires precision. That's why they're still in the laboratory phase.
How long before this becomes an actual treatment people can receive?
Years, realistically. They need to test in preclinical models first, then move to human trials if those results hold. Even if everything goes smoothly, you're looking at five to ten years minimum. But the mechanism is proven in cells, which is a significant step.
What happens if this doesn't work in living organisms the way it works in a dish?
That's always the risk. Cell culture is controlled. A living body is infinitely more complex. But the fact that roseoflavin worked even at very low concentrations suggests the pathway is robust enough to be therapeutically useful.